Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27835837 | 0.98 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL27919692 | 0.94 | ASIC3 (0.47) | PNMT | |
| SCHEMBL3252072 | 0.89 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL10798207 | 0.87 | ACHE (0.47) | — | |
| Bromide SCHEMBL9204144 | 0.85 | ACHE (0.46) | — | |
| Hydrochloric Acid SCHEMBL27919833 | 0.85 | ACHE (0.46) | — | |
| SCHEMBL21612906 | 0.85 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6952795 | 0.81 | ASIC3 (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL8234177 | 0.81 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1266520 | 0.79 | ITGB3 (0.51) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501036-B | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA | 2013-04-17 | — | — | CN | claimed |
| WO-2020009176-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | 田辺三菱製薬株式会社 | 2020-01-09 | — | — | WO | disclosed |
| CN-101501036-B | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA | 2013-04-17 | — | — | CN | disclosed |
| US-20110172416-A1 | AMIDINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2311810-A1 | AMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| CN-1522253-A | Novel heterocyclic derivatives and medicinal use thereof | ����ҩƷ��ҵ��ʽ���� | 2004-08-18 | — | — | CN | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0846115-A1 | NEW CYCLIC GUANIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS | Roche Diagnostics GmbH (DE) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008165-A1 | NEW CYCLIC GUANIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172416-A1 | AMIDINE DERIVATIVE | SERPINC1, F12, F11 | PNMT 4666/4885ADRA2A 3237/4885ADRA2B 2829/4885 |
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | PCCA, PPARA, PTGES | PNMT 54/4885ADRA2A 137/4885ADRA2B 439/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | PNMT 4121/4885ADRA2A 1070/4885ADRA2B 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.